

PRESS RELEASE

FOR IMMEDIATE PUBLICATION

NUTRASOURCE DIAGNOSTICS INC. ACQUIRES DITEBA RESEARCH LABORATORIES INC.

Nutrasource Diagnostics Inc. (NDI), of Guelph, Ontario, Canada, is pleased to announce that it has acquired the business assets of Diteba Research Laboratories Inc. (Diteba) of Mississauga, Ontario, Canada. The acquisition will allow NDI to expand its in-house bioanalytical capabilities with the addition of key scientific personnel and advanced analytical chemistry equipment to expand on its innovative new biological and analytical testing methods.

Diteba will operate as a wholly owned subsidiary of NDI under the corporate name of NDI ADRL Inc. to provide ingredient, product and bioanalytical services in the areas of method development, validation and routine testing services associated with NDI's Product Analytics, Human Diagnostics, Pharmaceutical Drug Development and Dietary Supplement Clinical Trials divisions.

Diteba will continue to offer its advanced bioanalytical methods to its existing customers in the biotechnology sector.

NDI will maintain their established and accredited network of suppliers of innovative analytical chemistry procedures.

About NDI

NDI has over ten years of international experience providing scientific research, product development, regulatory and quality services to the dietary supplement, natural health product, food, beverage and pharmaceutical industries. Services are offered as stand-alone capabilities or integrated into NDI's overall business model of helping companies bring preventative treatments to health and disease conditions to the market in a timely and cost-effective manner. NDI's product testing programs including the International Fish Oil Standards (IFOS) Program are renowned for the strict testing standards and ratings of omega-3 fish oil supplements while providing consumers with access to test result and score information (www.ifosprogram.com). Healthcare providers and researchers utilize NDI's Omega-3 Profile blood test and interpretation to measure the impacts of changes in diet and daily



supplementation.

About Diteba

Diteba is a world leader in complex bioanalytical test method development, validation and testing at our fully accredited facility in the greater Toronto area. Diteba's testing services are performed in accordance with the requirements of the US Food and Drug Administration (FDA), Health Canada and the International Conference on Harmonization (ICH) guidelines. Diteba is licensed by Health Canada as a GMP drug establishment and registered as a Drug Establishment with the U.S. FDA and is licensed by Health Canada to handle controlled drugs and substances. All operational aspects of Diteba's current service offerings will continue with no interruptions or significant changes that would impact Diteba's current licenses, thus ensuring full data integrity for all previous and ongoing clients.

If you have any questions or concerns, please do not hesitate to contact us. We sincerely appreciate your continuing support over the past few months and look forward to serving your science and laboratory needs in the future, with a renewed focus on service excellence.

For more information, please contact:

William J. Rowe, BA, President & CEO

Nutrasource Diagnostics Inc. 120 Research Lane, Suite 203 University of Guelph Research Park Guelph, Ontario, Canada N1G 0B4

T: 519-341-3360 F: 888-531-3466

E: wrowe@nutrasource.ca

The statements contained herein may include statements of future expectations and other forward-looking statements that are based on management's current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements.

The company assumes no obligation to update any information contained herein.